PTD-DBM vs RU-58841
A side-by-side research comparison of PTD-DBM and RU-58841 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PTD-DBM | RU-58841 |
|---|---|---|
| Full name | PTD-DBM (Wnt Pathway Hair Peptide) | RU-58841 (PSK-3841) |
| Category | Hair Growth | Hair Growth |
| Status | Research peptide (topical) | Research compound |
| Mechanism | PTD-DBM disrupts the interaction between CXXC5 and Dishevelled, releasing a natural brake on the Wnt/beta-catenin signaling pathway. Enhanced Wnt signaling promotes hair follicle neogenesis and regeneration. | Non-steroidal androgen receptor antagonist with high binding affinity. Applied topically, penetrates to dermal papilla cells where it blocks DHT-AR complex formation, preventing transcription of hair-miniaturizing genes without systemic antiandrogen effects. |
| Molecular weight | ~ (short cell-penetrating peptide) | 369.34 Da |
| Half-life | Topical (local action) | ~1 hour (in skin/plasma); active at receptor for 8-12h |
| Bioavailability | Topical (local delivery) | Topical only - minimal systemic absorption |
| Typical dose | Topical scalp application (research) | 50-100 mg in 1mL vehicle |
| Frequency | Daily | Daily application to scalp |
| Route | Topical | Topical (dissolved in ethanol/PG vehicle) |
PTD-DBM reported benefits
- Activates Wnt/beta-catenin hair pathway
- Promotes follicle neogenesis (research)
- Synergy with valproic acid
- Non-hormonal hair mechanism
RU-58841 reported benefits
- Local anti-androgen (no systemic effects)
- No sexual side effects
- DHT blocking at follicle level
- Can combine with oral finasteride
- Fast-acting (visible in weeks)
Related comparisons
Research and educational reference only. Not medical advice.